Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice.

Sasu BJ, Hartley C, Schultz H, McElroy P, Khaja R, Elliott S, Egrie JC, Browne JK, Begley CG, Molineux G.

Acta Haematol. 2005;113(3):163-74.

PMID:
15870486
2.

Control of rHuEPO biological activity: the role of carbohydrate.

Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I.

Exp Hematol. 2004 Dec;32(12):1146-55.

PMID:
15588939
3.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.

Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA.

Exp Hematol. 2003 Apr;31(4):290-9.

PMID:
12691916
4.

Enhancement of therapeutic protein in vivo activities through glycoengineering.

Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J.

Nat Biotechnol. 2003 Apr;21(4):414-21. Epub 2003 Mar 3.

PMID:
12612588
5.

Development and characterization of darbepoetin alfa.

Egrie JC, Browne JK.

Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):13-22. Review.

6.

Development and characterization of novel erythropoiesis stimulating protein (NESP).

Egrie JC, Browne JK.

Nephrol Dial Transplant. 2001;16 Suppl 3:3-13. Review.

PMID:
11402085
7.

Development and characterization of novel erythropoiesis stimulating protein (NESP).

Egrie JC, Browne JK.

Br J Cancer. 2001 Apr;84 Suppl 1:3-10. Review.

8.

Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J.

J Am Soc Nephrol. 1999 Nov;10(11):2392-5.

9.

Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.

Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM.

Clin Nephrol. 1999 Jun;51(6):367-72.

PMID:
10404697
10.

Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin.

Zhan H, Liu B, Reid SW, Aoki KH, Li C, Syed RS, Karkaria C, Koe G, Sitney K, Hayenga K, Mistry F, Savel L, Dreyer M, Katz BA, Schreurs J, Matthews DJ, Cheetham JC, Egrie J, Giebel LB, Stroud RM.

Protein Eng. 1999 Jun;12(6):505-13.

PMID:
10388848
11.

NMR structure of human erythropoietin and a comparison with its receptor bound conformation.

Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS.

Nat Struct Biol. 1998 Oct;5(10):861-6.

PMID:
9783743
12.

Efficiency of signalling through cytokine receptors depends critically on receptor orientation.

Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM.

Nature. 1998 Oct 1;395(6701):511-6.

PMID:
9774108
13.

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA.

N Engl J Med. 1998 Aug 27;339(9):584-90.

14.

Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.

Cowgill LD, James KM, Levy JK, Browne JK, Miller A, Lobingier RT, Egrie JC.

J Am Vet Med Assoc. 1998 Feb 15;212(4):521-8.

PMID:
9491159
15.

Epitope mapping and immunoneutralization of recombinant human stem-cell factor.

Mendiaz EA, Chang DG, Boone TC, Grant JR, Wypych J, Aguero B, Egrie JC, Langley KE.

Eur J Biochem. 1996 Aug 1;239(3):842-9.

16.

Isolation and characterization of conformation sensitive antierythropoietin monoclonal antibodies: effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure.

Elliott S, Chang D, Delorme E, Dunn C, Egrie J, Giffin J, Lorenzini T, Talbot C, Hesterberg L.

Blood. 1996 Apr 1;87(7):2714-22.

PMID:
8639887
17.

Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.

Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE, Egrie JC, Okamoto DM, Goodkin DA.

Am J Kidney Dis. 1995 Aug;26(2):331-40.

PMID:
7645538
18.

Effects of recombinant human erythropoietin and interleukin-3 on erythropoietic recovery from acute anemia.

Rosen BS, Levine EA, Egrie JC, Sehgal LR, Greenberg R, Rosen AL, Levine HD, Gould SA.

Exp Hematol. 1993 Oct;21(11):1487-91.

PMID:
8405228
19.

A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects.

Eschbach JW, Haley NR, Egrie JC, Adamson JW.

Kidney Int. 1992 Aug;42(2):407-16.

20.

Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor.

Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID.

Blood. 1992 Jul 1;80(1):60-7.

PMID:
1377054
21.

Erythropoietin deficiency after coronary artery bypass procedures.

Levine EA, Rosen AL, Sehgal LR, Gould SA, Egrie JC, Moss GS.

Ann Thorac Surg. 1991 May;51(5):764-6.

PMID:
2025080
22.

The safety of epoetin-alpha: results of clinical trials in the United States.

Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.

Contrib Nephrol. 1991;88:72-80. No abstract available.

PMID:
2040198
23.

The erythropoietic effects of interleukin 6 and erythropoietin in vivo.

Ulich TR, del Castillo J, Yin SM, Egrie JC.

Exp Hematol. 1991 Jan;19(1):29-34.

PMID:
1989892
24.

Recombinant human erythroid potentiating activity enhances the effect of erythropoietin in mice.

Niskanen E, Gasson JC, Egrie J, Wipf K, Golde DW.

Eur J Haematol. 1990 Nov;45(5):267-70.

PMID:
2261953
25.
26.

The cloning and production of recombinant human erythropoietin.

Egrie J.

Pharmacotherapy. 1990 Mar-Apr;10(2 ( Pt 2)):3S-8S.

PMID:
2345709
27.

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al.

Ann Intern Med. 1989 Dec 15;111(12):992-1000.

PMID:
2688507
28.

Perioperative recombinant human erythropoietin.

Levine EA, Gould SA, Rosen AL, Sehgal LR, Egrie JC, Sehgal HL, Levine HD, Moss GS.

Surgery. 1989 Aug;106(2):432-7; discussion 437-8.

PMID:
2763040
29.

Treatment of acute postoperative anemia with recombinant human erythropoietin.

Levine EA, Rosen AL, Sehgal LR, Gould SA, Egrie JC, Sehgal HL, Moss GS.

J Trauma. 1989 Aug;29(8):1134-8; discussion 1138-9.

PMID:
2760953
30.

USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients.

Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW.

Contrib Nephrol. 1989;76:160-5; discussion 212-8. No abstract available.

PMID:
2684518
31.

Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide.

Broudy VC, Lin N, Egrie J, de Haën C, Weiss T, Papayannopoulou T, Adamson JW.

Proc Natl Acad Sci U S A. 1988 Sep;85(17):6513-7.

32.

Recombinant human erythropoietin and autologous blood donation.

Levine EA, Rosen AL, Gould SA, Sehgal LR, Egrie JC, Browne JK, Sehgal HL, Moss GS.

Surgery. 1988 Aug;104(2):365-9.

PMID:
3400066
33.

The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.

Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W.

Behring Inst Mitt. 1988 Aug;(83):188-92.

PMID:
3071336
34.

The anemia of end-stage renal disease: hematopoietic progenitor cell response.

Segal GM, Eschbach JW, Egrie JC, Stueve T, Adamson JW.

Kidney Int. 1988 May;33(5):983-8.

35.

Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen.

Egrie JC, Cotes PM, Lane J, Gaines Das RE, Tam RC.

J Immunol Methods. 1987 May 20;99(2):235-41.

PMID:
3584994
36.

Biochemical analyses of murine erythropoietin from plasma and from cloned erythroleukemia cells.

Choppin J, Egrié J, Casadevall N, Lacombe C, Muller O, Varet B.

Exp Hematol. 1987 Feb;15(2):171-6.

PMID:
3469104
37.

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.

N Engl J Med. 1987 Jan 8;316(2):73-8.

PMID:
3537801
38.

Characterization and biological effects of recombinant human erythropoietin.

Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R, Trail G, Lin FK, Browne JK, Hines DK.

Immunobiology. 1986 Sep;172(3-5):213-24.

PMID:
3542810
39.

Megakaryocyte colony stimulating activity of recombinant human and monkey erythropoietin.

Dukes PP, Egrie JC, Strickland TW, Browne JK, Lin FK.

Prog Clin Biol Res. 1986;215:105-9. No abstract available.

PMID:
3725774
40.

Erythropoietin: gene cloning, protein structure, and biological properties.

Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E, Stebbing N.

Cold Spring Harb Symp Quant Biol. 1986;51 Pt 1:693-702. No abstract available.

PMID:
3472747
41.

Monkey erythropoietin gene: cloning, expression and comparison with the human erythropoietin gene.

Lin FK, Lin CH, Lai PH, Browne JK, Egrie JC, Smalling R, Fox GM, Chen KK, Castro M, Suggs S.

Gene. 1986;44(2-3):201-9.

PMID:
2877922
42.

Cloning and expression of the human erythropoietin gene.

Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, et al.

Proc Natl Acad Sci U S A. 1985 Nov;82(22):7580-4.

43.

Characterization of recombinant monkey and human erythropoietin.

Egrie JC, Browne J, Lai P, Lin FK.

Prog Clin Biol Res. 1985;191:339-50.

PMID:
2996025
44.

Are the sea urchin mitotic Ca2+-ATPase and Ca2+-sequestering activities affected by calmodulin?

Egrie JC, Nagle BW.

Ann N Y Acad Sci. 1980;356:376-7. No abstract available.

PMID:
6453546
45.

Changes in poly(adenylic acid) polymerase activity during sea urchin embryogenesis.

Egrie JC, Wilt FH.

Biochemistry. 1979 Jan 23;18(2):269-74. No abstract available.

PMID:
420784
46.

Adrenal medullary cyclic nucleotide phosphodiesterase. Subcellular distribution, partial purification and regulation of enzyme activity.

Egrie JC, Siegel FL.

Biochim Biophys Acta. 1977 Aug 11;483(2):348-66. No abstract available.

PMID:
196651
47.

Regional, cellular and subcellular distribution of calcium-activated cyclic nucleotide phosphodiesterase and calcium-dependent regulator in porcine brain.

Egrie JC, Campbell JA, Flangas AL, Siegel FL.

J Neurochem. 1977 Jun;28(6):1207-13. No abstract available.

PMID:
195013
48.

Adrenal medullary cyclic nucleotide phosphodiesterase: lack of activation by the calcium-dependent regulator.

Egrie JC, Siegel FL.

Biochem Biophys Res Commun. 1975 Nov 17;67(2):662-9. No abstract available.

PMID:
173325

Supplemental Content

Support Center